During the ongoing eighth China International Import Expo (CIIE), the Lin-gang Special Area Administration signed a strategic cooperation agreement with the Lingang Group's logistics platform and VISEN Pharmaceuticals on Nov 6.

This partnership will leverage the preferential policies of the special comprehensive bonded zone within Lin-gang to provide VISEN with a full-service solution covering customs clearance, international supply chains, and bonded R&D, accelerating the commercialization of VISEN's flagship growth hormone product.

A strategic cooperation agreement is inked by the Lin-gang Special Area Administration, the Lingang Group's logistics platform and VISEN Pharmaceuticals on Nov 6. [Photo/VISEN Pharmaceuticals]

VISEN Pharmaceuticals, a biotech firm specializing in endocrine therapies, showcased its innovative dual-chamber freeze-dried formulation technology at the CIIE. This breakthrough allows drugs to be stored stably at room temperature without preservatives, making administration easier for patients. By partnering with industry leader Tofflon, VISEN aims to bridge gaps in domestic dual-chamber delivery systems and ensure production meets global standards.

The agreement underscores Lin-gang's role as a hub for cutting-edge healthcare innovation, offering tailored support to international firms. Meanwhile, VISEN's participation highlights China's growing appeal as a launchpad for global biotech advancements, fostering synergies between domestic policy incentives and cross-border expertise.

This collaboration reflects Lin-gang's commitment to nurturing high-value industries and driving mutually beneficial outcomes in an increasingly interconnected global economy.